Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial

2016348 citationsJournal Articlehybrid Open Access

Authors

Lyndon da Cruz · Moorfields Eye Hospital NHS Foundation Trust

Jessy D. Dorn · Second Sight Medical Products

Mark S. Humayun · University of Southern California

Gislin Dagnelie · Johns Hopkins University

James T. Handa · Johns Hopkins University

Pierre‐Olivier Barale · Centre hospitalier national d'ophtalmologie des Quinze-Vingts

José‐Alain Sahel

Abstract

The 5-year results of the Argus II trial support the long-term safety profile and benefit of the Argus II System for patients blind as a result of RP. The Argus II is the first and only retinal implant to have market approval in the European Economic Area, the United States, and Canada.

Topics & Keywords

Neuroscience and Neural Engineering Retinal Development and Disorders Advanced Memory and Neural Computing

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Ophthalmology

Volume 123, Issue 10, pp. 2248-2254

DOI: 10.1016/j.ophtha.2016.06.049

Field-Weighted Citation Impact: 21.34